Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CPBY - Took my profits on this one prior to earnings...After the BSPM episode last week, I learned my lesson...I can always jump back in...Aggie.....
I am in for 3K averaged at 3.78. Still down, but expecting uplisting news this month. Hoping uplisting news will push us to $5's. Will wait and see.....Aggie...
Double Post sorry
BSPM - Holy crap...Was the 2010 guidance so bad today to warrent this huge selloff????? I thought they were about what this board was expecting...Aggie.....
EVRM - Anyone still in this? Any hope for recovery? Aggie...
Have 1M at .0007 and about 1.6M at .0006...Looking for the .001 break again....Aggie....
Some more Country Songs....
Real Country-Western Song Titles
I'll Marry You Tomorrow But Let's Honeymoon Tonight
Dog Poop On The Pillow Where Your Sweet Head Used To Be
I Just Bought A Car From A Guy That Stole My Girl, But The Car Don't Run So I Figure We're Even
I Liked You Better Before I Knew You So Well
She's Looking Better After Every Beer
I Wouldn't Take Her To A Dog Fight, 'Cause I'm Afraid She'd Win
I Ain't Gone To Bed With No Ugly Women, But I Shore Woke Up With A Few
I'm So Miserable Without You, It's Like Having You Here
I've Got Tears In My Ears From Lyin' On My Back and Cryin' Over You
Please Bypass This Heart
You Done Tore Out My Heart And Stomped That Sucker Flat
She's Actin' Single and I'm Drinkin' Doubles
Drop Kick Me, Jesus, Through The Goalposts Of Life
If I'd Shot You When I Wanted To, I'd Be Out Of The Pen By Now
Get Your Tongue Outta My Mouth 'Cause I'm Kissing You Goodbye
I Still Miss You, Baby, But My Aim's Gettin' Better
Her Teeth Were Stained, But Her Heart Was Pure
How Can I Miss You If You Won't Go Away?
I Changed Her Oil, She Changed My Life
I Don't Know Whether To Kill Myself Or Go Bowling
I Fell In A Pile Of You And Got Love All Over Me
I Keep Forgettin' I Forgot About You
I Wanna Whip Your Cow
I Would Have Wrote You A Letter, But I Couldn't Spell Yuck!
I Wouldn't Take Her To A Dawg Fight, Cause I'm Afraid She'd Win
I'd Rather Have A Bottle In Front Of Me Than A Frontal Lobotomy
I'm Just A Bug On The Windshield Of Life
If I Can't Be Number One In Your Life, Then Number Two On You
If My Nose Were Full of Nickels, I'd Blow It All On You
If The Phone Doesn't Ring, It's Me
Mama Get The Hammer (There's A Fly On Papa's Head)
My Head Hurts, My Feet Stink, And I Don't Love Jesus
My John Deere Was Breaking Your Field, While Your Dear John Was Breaking My Heart
My Wife Ran Off With My Best Friend, And I Sure Do Miss Him
Oh, I've Got Hair Oil On My Ears And My Glasses Are Slipping Down, But Baby I Can See Through You
She Got The Gold Mine And I Got The Shaft; She Got The Ring And I Got The Finger
Thank God And Greyhound She's Gone
You Can't Have Your Kate And Edith Too
You Were Only A Splinter In My Ass As I Slid Down The Bannister Of Life
You're The Reason Our Kids Are So Ugly
The MM's kicked my butt on PUDA today. I was away from my office all morning and put in a trailing stop at 6.10 before markets opened. Stock up big two consequtive days, figured it might drop and I wanted to lock in my profits (in from 5.20). Well the MM's dropped it to 6.10 to take out my sell and then took it up to 6.90 eod. Anyone have a strategy to protect my profits, but not get screwed by the MM's. Cant watch my stocks all day because of work...Aggie....
I played this one last year all the way from 2.40's to .75...Had about a $1.50 gap down overnight on news European regulator rejected the Oncophage. I have not been following this one. Can you post anything that suddenly makes this a screaming buy?
http://finance.yahoo.com/news/European-CHMP-Formally-Adopts-bw-739832832.html?x=0&.v=1
Lost my A@@...I wish you luck, but I still have a bitter taste in my mouth over AGEN. If you have anything to support your prediction, please post...Aggie...
I hate to burst you bubble, but no way this is going to AMEX with only 150K profits and trading at .14...IMO...Disclaimer: I am averaged in at .295 hoping for another pop to .30's.....Aggie..
Wow. .0001 At least we dont go unlower than this unless we get into a no bid situation. I might want to put a bid out at .0001 just so that does not happen....unreal how far the officers of this company have let it fall....Aggie....
ACHN news... UP Premarket...$5 Target
Wedbush upgrades Achillion Pharmaceuticals (Nasdaq: ACHN) from Neutral to Outperform. Price target $5.
Wedbush analyst says, "Our increased confidence of an ACH-1625 partnership, which if materialized, could move the stock to our PT of $5. (1) Data from the first two cohorts from the Phase Ib study suggest that ACH-1625’s single agent potency (3.94-4.25 log drop) measures at the high end of the range among the HCV PIs in the clinic (the highest short term single agent viral load drop reported is 4.6 log), and the prolonged viral suppression after 5 days of dosing may indicate a robust resistance profile in addition to high potency, which can be a differentiating point for ACH-1625 among the PIs; (2) Our increasing conviction that serious HCV players in the industry need to position themselves for the STAT-C combination game during 2010, and it appears to us that there are more players than attractive HCV assets that are available. As few companies have more than two classes of molecules in their pipeline, we expect elevated level of deal-making activities in 2010."
http://www.streetinsider.com/Upgrades/Wedbush+Upgrades+Achillion+Pharmaceuticals+%28ACHN%29+to+Outperform/5297674.html
More ACHN news... UP Premarket...$5 Target
Wedbush upgrades Achillion Pharmaceuticals (Nasdaq: ACHN) from Neutral to Outperform. Price target $5.
Wedbush analyst says, "Our increased confidence of an ACH-1625 partnership, which if materialized, could move the stock to our PT of $5. (1) Data from the first two cohorts from the Phase Ib study suggest that ACH-1625’s single agent potency (3.94-4.25 log drop) measures at the high end of the range among the HCV PIs in the clinic (the highest short term single agent viral load drop reported is 4.6 log), and the prolonged viral suppression after 5 days of dosing may indicate a robust resistance profile in addition to high potency, which can be a differentiating point for ACH-1625 among the PIs; (2) Our increasing conviction that serious HCV players in the industry need to position themselves for the STAT-C combination game during 2010, and it appears to us that there are more players than attractive HCV assets that are available. As few companies have more than two classes of molecules in their pipeline, we expect elevated level of deal-making activities in 2010."
http://www.streetinsider.com/Upgrades/Wedbush+Upgrades+Achillion+Pharmaceuticals+%28ACHN%29+to+Outperform/5297674.html
That is the funniest thing I have ever read....Reminds me of when my 10 year old brother pee'ed on electric fence around the garden back home.....Aggie...
Somebody fat finger a trade at .02? Maybe they wanted at .002 instead. If so, expensive mistake.....Aggie....
IMO...No audit news...No sale news...Audited financials has been "almost ready" since January 2009...This is not by some unknown poster on IHUB, but from the company itself...
NEW YORK, NY -- (Marketwire) -- 01/23/09 -- Winmax Trading Group, Inc. (Winmax) (PINKSHEETS: WNMX) is currently in the process of completing all statutory required financials and corporate information. Management is of the opinion that the financial statements and required audits will be completed in the very near future.
The Company invites its shareholders, stakeholders, and interested participants to be informed and up to date on the company by registering on the company's website www.winmaxtradinggroup.com and receive the weekly newsletter from Winmax Trading Group subsidiary, bnetTV.com, Inc., on www.bnettv.com.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause the actual financial or operating results of Winmax Trading Group, Inc. and its subsidiaries, including bnetTV, Inc. thegemstore.com, Inc. Winmax Media, Inc.(hereafter collectively referred to as "the Company," "we," "our" or "us") to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. The words or phrases "would be," "may allow," "intends to," "may likely," "are expected to," "may continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Such statements include those concerning our expected financial performance, our corporate strategy and operational plans. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties, including: (a) intense competition in the webcasting, online media, web development design, Internet solutions, e-commerce, and retail E-business; (b) whether we are able to manage our planned growth efficiently, including whether our management will be able to identify, hire, train, retain, motivate, and manage required personnel or that management will be able to manage and exploit existing and potential market opportunities successfully; (c) whether we are able to generate sufficient revenues or obtain financing to sustain and grow our operations. bnetTV.com, Inc., TheGemstore.com, Inc., and Winmax Media, Inc. all are wholly owned subsidiary of Winmax Trading Group, Inc. All of the agreements and event coverage that each of the subsidiaries have entered into should not be construed by any means whatsoever as having any impact on or a reflection of the Company's future stock price or future financial results.
For further information, please contact:
Dave Young
Vice President and Investor Relations
Phone: 877 693-3130
Email: Email Contact
http://www.winmaxtradinggroup.com
ACHN News...Not sure if it has been posted yet.
Achillion Announces Nomination of ACH-2684 as Lead Clinical Candidate in Resistance-Focused HCV Program
Compound Demonstrates Excellent Potency Against HCV and Retains Activity Against Resistant Variants
NEW HAVEN, Conn., Jan. 28, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the nomination of a lead clinical candidate in its third proprietary program against hepatitis C infection. The candidate, ACH-2684, demonstrates excellent potency in the low pico-molar range, as well as good pharmacokinetic and safety profiles in pre-clinical studies
http://finance.yahoo.com/news/Achillion-Announces-pz-798360296.html?x=0&.v=1
My guess is that if we ever get the PR on audited financials, then we can expect the sale news to follow shortly. No one in their right mind is gonna buy anything without audited financials. Period. Until the audit news hits, this stock is going to drift between .006 and .0012. I am gonnna play that range unless something substantial hits the wires. IMHO.....
Aggie
IMO this is the reason for the latest drop. 2nd quarter is anytime between April and June (if there is not another delay). Most of the people looking for a moon shot dont want to have their money tied up for that long. Me, I am in at .0007 and looking for .001...Good luck...Aggie...
I have lost about 35% of my trading account over the past two weeks. CCME, BSPM, LLEN, YONG, TPI, CMFO, GRRF. All my Chinese Small caps taking huge hits. Doubled down until I have nothing left but bags. Hoping these come back, but looks like I am out of the game for awhile. I am definantly going to have to reevaluate my trading strategy. Cant sit at the computer and baby sit all day long. Very disappointing....Good luck everybody....Aggie....
Very nice Rames...Membermark sir!
Aggie..
1M @ .0007 on Friday. Will double down if anything lower is available. Hoping for .0012 again...Aggie....
I am not in again yet, but I do have my order in at 7... Here is snippit of the PR dated a year ago stating audited financials were just about ready...Dont hold your breath thinking the 2010 version of the rumor will be any different.
NEW YORK, NY--(MARKET WIRE)--Jan 23, 2009 -- Winmax Trading Group, Inc. (Winmax) (Other OTC:WNMX.PK - News) is currently in the process of completing all statutory required financials and corporate information. Management is of the opinion that the financial statements and required audits will be completed in the very near future.
http://finance.yahoo.com/news/Update-on-iw-14140318.html?x=1
The closing price on that date was .02. What a wonderful job Skylar and Young have done in running this company into the ground over the past year.
http://bigcharts.marketwatch.com/historical/default.asp?detect=1&symbol=WNMX&close_date=01%2F23%2F2009&x=34&y=14
Aggie....
APWR... 13.02
SHENYANG, China, Jan. 21 /PRNewswire-Asia-FirstCall/ -- A-Power Energy Generation today announced that it has closed a private placement for $83 million in cash with several institutional investors. The net proceeds from the placement will be used to fund a portion of the purchase price of the Company's previously announced EVATECH acquisition and the remainder of the net proceeds have been designated for investment in additional components for the manufacturing of turbines, funding of existing projects and additional working capital.
The Company issued to institutional investors 5,777,932 Common Shares ("Shares") at a price of $14.37 per share. In addition, the Company issued to the investors warrants to purchase an aggregate of 2,888,966 Shares, 2,099,822 of the warrants are exercisable at $16.90 per Share and the remainder are
Anyone (besides me!) pick up RINO yesterday at $22-$23...Trading $25+ PM on news.
RINO Signs Sinter Flue Gas Desulphurization BOT Contracts with Shougang Jingtang Iron & Steel Co., Ltd. Valued at $118 million
DALIAN, China, Jan. 22 /PRNewswire-Asia-FirstCall/ --
RINO International Corp. (NASDAQ:RINO), which through its subsidiaries and controlled affiliates (collectively, the "Company" or "RINO"), designs, manufactures, installs and services proprietary and patented wastewater treatment, desulphurization equipment, and high temperature anti-oxidation systems for iron and steel manufacturers in the People's Republic of China ("PRC"), today announced that it signed Sinter Flue Gas Desulphurization BOT (Build-Operate-Transfer) contracts with Shougang Jingtang Iron & Steel Co., Ltd. The BOT contracts consist of a build contract and an operating contract, valued at a total of $118 million. Shougang Jingtang Iron & Steel Co., Ltd. is owned 51% by Shougang Iron & Steel and 49% by Tangshan Iron & Steel Co., Ltd
The build contract, valued at $33.8 million, includes $25.8 million construction principal and $8 million in interest, covers the design, construction and installation of two Semi-Dry Flue Gas Desulphurization ("FGD") Units, each of which is approximately 500 square meters in size, which collectively produce approximately 11 million tons of sinter mine annually. The project commenced at the Hebei Province Tangshan City Caofeidian Industry zone facility with initial engineering design work on January 1, 2010 and the installation will be completed by September 30, 2010. RINO anticipates these systems will filter at least 91.7% of the sulphur dioxide produced, from sinter mines
The customer will make an initial payment of $4.0 million one year after the FGD Units have received product approval by the customer and environmental acceptance by the State Environmental Protection Department. The balance of the build contract amount will be paid in annual installments of approximately $3.0 million, which includes interest at a blended rate of 5.75%. Gross margins associated with the build contract are estimated at approximately 38%
The operating contract, valued at approximately $84.3 million, has a 10- year term, will commence upon receipt of final State Environmental Protection Department approval. RINO will be responsible for daily operation of the two FGD Units installed under the build contract. This includes obtaining desulfurization supplies such as lime, and utilities, such as process water, power and compressed air, in addition to staff salaries, maintenance repair and FGD ash handling fees. Under the operating contract, the customer shall make annual payments to RINO of approximately $8.24 million through monthly installments. RINO will bear the utility expenses estimated at $6.21 million annually, which are the largest component of the operating costs. RINO will also receive $1.9 million for maintenance upgrades of the FGD Units in the fifth year
After the final payments under the BOT Contracts, the ownership of the FGD Units will be transferred to Shougang Jingtang Iron & Steel Co., Ltd
"We are extremely pleased to finalize this contract with Shougang Jingtang Iron & Steel Co., Ltd, a top Steel Producer in China with annual production of approximately 10 million tons," stated Mr. Zou Dejun, President and CEO of RINO International. "Shougang Jingtang Iron & Steel Co., Ltd. currently operates two sinters at its newly established production facilities measuring 1,000 square meters in total capacity. The Company has plans to double its capacity in the near term, which will create an incremental future opportunity for additional FDG systems."
"This is the first BOT agreement signed to date and is a means for meeting our customers' operating objectives while providing long term recurring revenue for RINO. This is a true win-win for both parties. We are encouraged by this new model and believe it will serve as a model for future agreements with top tier steel producers as the government continues to support installation of flue gas desulphurization systems and more actively regulates emission standards."
ABOUT RINO INTERNATIONAL
We are an industrial technology-based environmental protection and remediation company based in China. Specifically, through our subsidiaries and controlled affiliates in China, we are engaged in the business of designing, manufacturing, installing and servicing wastewater treatment and exhaust emission desulphurization equipment principally for use in China's iron and steel industry, and anti-oxidation products and equipment designed for use in the manufacture of hot rolled steel plate products. All of our products are custom-built for specific project installations, and we execute supply contracts during the design phase of our projects. Our products are all designed to reduce industrial pollution, energy utilization, or both
For more information, please contact:
For the Company: Jenny Liu Tel: +86-411-8766-2700 Email:
Investors: Matt Hayden HC International, Inc
Tel: +1-561-245-5155 Email:
DATASOURCE: RINO International Corp
CONTACT: Jenny Liu, +86-411-8766-2700, ; or
Investors, Matt Hayden of HC International, Inc., +1-561-245-5155,
TSTC - Wow!! Flipped twice today from 18.50 to 19.00 and 18.75 to 19.20. Last I looked it was 19.30ish and still heading up...30 minutes later looked again and below 18.00...Unreal...Aggie....
EDS...Nice day...Riding CCME MOMO???...Aggie....
DRRX news 2.48 +7.36%
DURECT Initiates U.S. Pivotal Phase III POSIDUR(TM) Clinical Trial
7:00a ET January 19, 2010 (PR NewsWire)
DURECT Corporation (Nasdaq: DRRX) announced today that it has begun dosing patients in its U.S. pivotal Phase III clinical trial to evaluate POSIDUR(TM) (SABER(TM)-Bupivacaine), an investigational drug, for the treatment of post-surgical pain. The pivotal trial, referred to as BESST (Bupivacaine Effectiveness and Safety in SABER Trial), is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in patients undergoing general surgical procedures. We expect to enroll approximately 300 patients at approximately 20 clinical trial sites in the study.
"Initiation of our Phase III BESST program represents a significant milestone for DURECT," stated James E. Brown, President and CEO of DURECT Corporation. "We believe that POSIDUR, if approved, could improve the treatment of patients' post-surgical pain and reduce the use of opioids in this setting."
"BESST was designed based on feedback from the FDA as well as input from expert consultants and key opinion leaders," stated Joe Stauffer, Chief Medical Officer of DURECT Corporation. "We anticipate completing enrollment in the first half of 2011."
About the Design of BESST
BESST is an international, multi-center, randomized, double-blind, controlled trial evaluating the safety, efficacy, effectiveness, and pharmacokinetics of POSIDUR in approximately 300 patients undergoing a variety of general abdominal surgical procedures. Eligible patients will be randomly assigned to one of three cohorts:
Cohort 1: An active comparator cohort in which patients are randomized to receive either POSIDUR 5.0 mL or commercially available Bupivacaine HCl solution after laparotomy.
Cohort 2: An active comparator cohort in which patients are randomized to receive either POSIDUR 5.0 mL or commercially available Bupivacaine HCl solution after laparoscopic cholecystectomy.
Cohort 3: A double blind, placebo controlled cohort in which patients are randomized to receive either POSIDUR 5.0 mL or SABER-Placebo after laparoscopically-assisted colectomy.
Efficacy evaluation in the BESST trial will encompass a number of parameters. The two co-primary efficacy endpoints for Cohort 3 will be mean pain intensity on movement (normalized) Area Under the Curve (AUC) during the period 0-72 hours post-dose and mean total morphine equivalent opioid dose for supplemental analgesia during the period 0-72 hours post-dose. An adaptive feature of BESST allows for upsizing of the patient sample size in Cohort 3 based on pooled and blinded data. The purpose of Cohorts 1 and 2 is to give us additional experience with the use of POSIDUR in a broader group of surgeries and patients.
About the DURECT / Nycomed Collaboration
In November 2006, DURECT signed a collaboration agreement with Nycomed, a privately-held European pharmaceutical company headquartered in Switzerland, whereby DURECT has licensed Nycomed the exclusive commercialization rights to POSIDUR in the European Union (E.U.) and select other countries. In addition, under the agreement, DURECT will manufacture and supply the product to Nycomed for commercial sale in the territory licensed to Nycomed. DURECT retains full ownership of POSIDUR in the U.S., Canada, Asia and other countries.
The agreement currently provides for the two parties to jointly direct and equally fund a development program for POSIDUR intended to secure regulatory approval in both the U.S. and the E.U. However, DURECT and Nycomed are currently negotiating an amendment to the agreement intended to give DURECT and Nycomed each the sole, final decision making authority and financial responsibility for the remaining clinical programs for the U.S. in the case of DURECT and the E.U. in the case of Nycomed. This proposed amendment reflects the divergence between the clinical development programs required for regulatory approval as between the U.S. and E.U. while preserving the close cooperation and sharing of data for the mutual benefit of both parties. As the parties are negotiating this proposed amendment, DURECT is solely responsible for funding BESST.
Conference Call
A live audio webcast of a conference call to discuss BESST will be broadcast over the internet at 11:00 a.m. Eastern Time on January 19 and is available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
POSIDUR
POSIDUR is a long-acting local anesthetic under development by DURECT and Nycomed for the treatment of post-surgical pain. It is intended to be administered during surgery, where it continuously releases therapeutic levels of bupivacaine in a controlled fashion, providing up to 72 hours of uninterrupted local analgesia. POSIDUR's performance is due to DURECT's patented SABER(TM) delivery system, an injectable, biodegradable drug delivery technology.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM), and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the U.S. Food and Drug Administration or other health authorities.
DURECT Forward-Looking Statement
The statements in this press release regarding the BESST trial, potential uses and benefits of POSIDUR, and our agreement with Nycomed regarding future funding arrangements for the development program for POSIDUR are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's ability to enroll patients in the BESST trial in a timely manner, DURECT's reliance on third-party contract research organizations for the conduct of the BESST trial, potential side effects or adverse events observed during the BESST trial or in other clinical trials of POSIDUR, whether POSIDUR will meet the endpoints set forth in the BESST trial or in other clinical trials, whether DURECT will reach agreement with Nycomed regarding financial arrangements for the development program for POSIDUR, the companies potential difficulty or failure to agree upon the development plan and funding of the joint U.S. and E.U. development program, delays and costs due to additional work or other requirements imposed by regulatory agencies for continued development, approval or sale of POSIDUR, our ability to consummate collaborative agreements relating to POSIDUR, our ability to complete the design, development, and manufacturing process development of POSIDUR, and to manufacture, commercialize and obtain marketplace acceptance of POSIDUR, and avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on November 2, 2009 under the heading "Risk Factors."
SOURCE DURECT Corporation
LOL...Anyone who has been around this stock (and PRMO for that matter) knows that a POS Skylar is...IMO, this stock is for trading only...Buy at .0007 - .0008, sell at .0011 - .0012 (occasionally higher)...I made that trip 10 times in 2009 and once already in 2010...I looked back on Mr. Taki's post and he made it quite clear this is a trading stock, not a retirement plan...I really hope you get your moon shot here, but realisticly 2nd qtr now before any significant news...And Mr. Skylar does what he always does...Makes the PR vague enough that many will hold and hope...He will keep stringing everyone along and dump shares endlessly...That is his MO...Anyone who has been around one of his scams can vouch...Good luck man, you are going to need it....IMO...Aggie...
Anyone have thougths on TPI...Way underwater on this one...Hold, Fold, or double down...Thought last weeks news was great...Do not understand the .88 cent drop since news...Any comments would be greatly appreciated...Aggie...
No sale until 2nd qtr guys...I hope everyone locked in profits by now...Skylar is scum...
Aggie....
Winmax Re-Organizes bnetTV.com, Inc. Under Bnet Communications, Inc.
NEW YORK, NY -- (Marketwire) -- 01/19/10 --
bnetTV.com, Inc. (www.bnettv.com), a subsidiary of Winmax Trading Group, Inc. (Winmax) (PINKSHEETS: WNMX), is pleased to announce that it has re-organized its subsidiary bnetTV.com, Inc. under Bnet Communications, Inc
Over the last eight years bnetTV.com has covered Emerging Technology events globally gathering a significant video library and building an excellent reputation with the public and the industries it reports on. Most recently bnetTV reported on the world's largest tradeshow for consumer technology -- the Consumer Electronics Show (CES), in Las Vegas where the team interviewed 150 industry innovators, 4 times more than any other media outlet onsite
In February 2010, the bnetTV team will be in Barcelona, Spain covering the GSMA Mobile World Congress, where they anticipate interviewing up to 200 companies in the Wireless industry. Providing such comprehensive media coverage continues to drive bnetTV's market leadership in creating relevant and compelling content to a global audience
Several significant milestones in the creation of bnet Communications have recently been met and the Winmax Trading reaffirms that it will complete the sale during the second quarter of 2010. Several favorable events for bnetTV.com's business have also exceeded expectations and the company will continue with its plans to monetize its robust library of content through advertising, sponsorship, subscription models, and client commissioned services. 2010 online advertising trends indicate that video sites with deep catalogues and rich media experiences will drive advertising spend. bnetTV.com has well over 5000 videos with leading technology companies included in its video library. eMarketer analysts predict that video sites whose business models include a hybrid plan of advertising and subscription fees for premium content offerings are positioned to experience significant growth in 2010
President and CEO for Winmax Gerald Sklar commented, "Winmax's decision to re-organize its subsidiary bnetTV.com under Bnet Communications, Inc. is to leverage off of bnetTV's significant market value, creating additional growth opportunities for the company."
The Company invites its shareholders, stakeholders, and interested participants to be informed and up to date on the company by opting in at the company's website www.winmaxtradinggroup.com and receive the weekly newsletter from Winmax Trading Group's subsidiary bnetTV.com, Inc
www.bnettv.com
LOL...Not even close...I could care less if it goes back down...I hope everyone gets there moonshot this time around...Skylar is a crook, so be careful...
I follow Prof Charts picks very closely...I am also a member of Stockseasonality.com (Ken and Charts site)...I am trying to learn the setups...I think in the case of CCME and the unique warrant overhang situation, applying a setup is difficult...This is purely a value play...nothing more nothing less...BTW, I have 3K shares at an average of $12.02...For the small time portfolio I have, this holding represents about 50% of my trading $$$...I like a lot of others here have broken a lot of portfolio rules...I wish everyone the best....Aggie...
Good luck here guys...I got out at .0011 on Friday...I dont trust Uncle Gerry...Dont get caught holding Uncle Gerry's bag...I'll jump back in if we she ever drops below .0009 again...Played this stock 8 times in 2009 and once now in 2010...Just dont forget to take your profits and dont get played by Skylar...Best of luck everyone...Aggie.....
Please remove this dup post......
Out 1.5M @ .0011 from .0009 and .0007.....Aggie....
Anyone have a thought on the CMFO nosedive? Caught me by suprise....
ACHN - Big gap up on news for those still in...
OPXA - WOW!!! for those still in. I sold the pop yesterday and now wished I had held a bit longer....Aggie...
In today PM at 2.20.....Aggie.